Lilly makes US$2.4 Billion buy of early-stage companyJune 20, 2023 - "Under the terms of the deal, Lilly will buy all of DICE’s outstanding shares for $48 a pop, representing a 40% premium to the latter’s 30-day volume weighted average shares price as of last Friday. Lilly will make the payment in cash, amounting to an aggregate of around $2.4 billion."
DICE’s DELSCAPE platform has yielded two oral candidates that have begun early-stage clinical testing: DC-806 and DC-853 target the pro-inflammatory cytokine IL-17.
https://www.biospace.com/article/lilly-aims-to-boost-immuno-business-with-2-4b-dice-buy/